| Name | VERPROSIDE | 
|---|
| Description | Verproside, a catalpol derivative iridoid glycoside isolated from the genus Pseudolysimachion, represses TNF-α -induced MUC5AC expression by inhibiting NF-κB activation via the IKK/IκB signaling cascade. Verproside has potent anti-inflammatory, antioxidant, antinociceptive activities and ir is a potent anti-asthmatic/COPD drug candidate in vivo[1]. | 
|---|---|
| Related Catalog | |
| Target | 
                                
                                 NF-κB TNF-α IKK  | 
                        
| In Vitro | Verproside (2.5-20 μM; for 2 hours) markedly reduces phosphorylation levels of IKKα/β, IκBα, and TAK1 in the 5-20 μM range[1]. Western Blot Analysis[1] Cell Line: NCI-H292 cells Concentration: 2.5, 5, 10, 20 μM Incubation Time: 2 hours Result: Resulted in markedly reduced phosphorylation levels of IKKα/β, IκBα, and TAK1. | 
| In Vivo | Verproside (Intragastrically; 30 mg/kg; 48 hours) significantly reduces the immunoglobulin E (IgE) levels of verproside-treated mice[2]. Animal Model: Specific pathogen-free female BALB/c mice aged 8-10 weeks[2] Dosage: 30 mg/kg Administration: Intragastrically; 48 hours Result: Reduced significantly the immunoglobulin E (IgE) levels. | 
| References | 
| Density | 1.75±0.1 g/cm3(Predicted) | 
|---|---|
| Boiling Point | 822.9±65.0 °C(Predicted) | 
| Molecular Formula | C22H26O13 | 
| Molecular Weight | 498.43 | 
| Storage condition | ?20°C | 
| Symbol | 
                                
                                 
                                
                                GHS07  | 
                        
|---|---|
| Signal Word | Warning | 
| Hazard Statements | H319 | 
| Precautionary Statements | P305 + P351 + P338 | 
| Hazard Codes | Xi | 
| Risk Phrases | 36 | 
| Safety Phrases | 26 | 
| RIDADR | NONH for all modes of transport |